AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19711095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 17366346 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 24
Study 17366346 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 17366346 — intervention group
Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 24
Study 14644068 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of dexamethasone (DEX)
Number of subjects: 62
Study 11443153 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (genotropin 4 IU/m(2).day) and GnRHa (triptorelin, 3.75 mg/28 days)
Number of subjects: 36
Study 11443153 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 36
Study 9610711 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (n=106)
Number of subjects: 211
Study 9610711 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (n=105)
Number of subjects: 211
Study 9610711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Doxorubicin and Epirubicin
Number of subjects: 211
Study 8148931 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg dexfenfluramine (DF) twice daily
Number of subjects: 103
Study 8148931 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/200 mg ephedrine/caffeine (EC) three times a day
Number of subjects: 103
Study 8148931 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of patients with BMI >= 30 kg/m2 on DF
Number of subjects: 103
Study 8148931 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of patients with BMI >= 30 kg/m2 on EC
Number of subjects: 103
Study 8148931 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 103
Study 3491942 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual electrical stimulation with Audimax Theraband
Number of subjects: 30
Study 3491942 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 30
Study 31328607 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based personalized intervention for mothers
Number of subjects: 73
Study 31328607 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained mothers)
Number of subjects: 73
Study 29246819 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported contraceptive use (no hormonal contraceptive use in the previous 6 months)
Number of subjects: 97
Study 26829646 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 367
Study 26829646 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalysis (PA)
Number of subjects: 367
Study 26829646 — intervention group
Group type: COMPARATOR
Intervention: Short-term therapy
Number of subjects: 367
Study 26148362 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane-based anesthesia
Number of subjects: 125
Study 26148362 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-based anesthesia
Number of subjects: 125
Study 26148362 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane-based anesthesia with fentanyl
Number of subjects: 125
Study 23402525 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Psychological Intervention (MPI) administered by trained nurses in cognitive behavioural therapy and self-management.
Number of subjects: 124
Study 23402525 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 124
Study 21400388 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer, Lifting and Repositioning (TLR) program
Number of subjects: 766
Study 21400388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TLR program)
Number of subjects: 766
Study 18784526 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sterile solution of metronidazole (2 mL, 10 mg) incorporated in the sinus bone graft
Number of subjects: 72
Study 18784526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metronidazole)
Number of subjects: 72
Study 16898076 — intervention group
Group type: EXPERIMENTAL
Intervention: New retard tablet formulation (240mg oral)
Number of subjects: 12
Study 16898076 — intervention group
Group type: COMPARATOR
Intervention: Standard retard tablet formulation (240mg oral)
Number of subjects: 12
Study 16898076 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dose (5mg)
Number of subjects: 12
Study 14597782 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (3 mg in 10 ml saline)
Number of subjects: 48
Study 14597782 — intervention group
Group type: COMPARATOR
Intervention: Control (10 ml saline)
Number of subjects: 48
Study 11070572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine hydrochloride 135 mg t.i.d. (Colofac)
Number of subjects: 213
Study 11070572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine hydrochloride 200 mg b.i.d. (Colofac MR)
Number of subjects: 213
Study 11070572 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 213
Study 8612411 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor group (n = 10) with end-tidal CO2 monitoring
Number of subjects: 50
Study 8612411 — intervention group
Group type: COMPARATOR
Intervention: No-monitor group (n = 25)
Number of subjects: 50
Study 8612411 — intervention group
Group type: COMPARATOR
Intervention: Monitor-blind group (n = 25)
Number of subjects: 50
Study 1450803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injection (methylprednisolone and lignocaine)
Number of subjects: 11
Study 1450803 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (lignocaine alone)
Number of subjects: 11
Study 6363095 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of MA
Number of subjects: 18
Study 6363095 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg of MA
Number of subjects: 18
Study 6363095 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mg of MA
Number of subjects: 18
Study 31019730 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 124
Study 31019730 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study 29094178 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT + PSK
Number of subjects: 111
Study 29094178 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 111
Study 26884559 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by ifosfamide-containing salvage treatment and stem-cell transplantation for PET2-positive patients
Number of subjects: 519
Study 26884559 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for PET2-negative patients
Number of subjects: 519
Study 24771373 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipine
Number of subjects: 0
Study 24771373 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0
Study 24771373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 0
Study 24771373 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxypyridine derivatives (emoxipine and mexidol)
Number of subjects: 0
Study 22234614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreinforced X‐‐ B‐ presentations
Number of subjects: 0
Study 22234614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreinforced X‐‐ B‐ trials
Number of subjects: 0
Study 20871804 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy in home care (PST-HC)
Number of subjects: 38
Study 20871804 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus education intervention (Control)
Number of subjects: 38
Study 17617743 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib vaccine administered at 0, 4, and 8 weeks
Number of subjects: 0
Study 17617743 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib vaccine
Number of subjects: 0
Study 16344017 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized rehabilitation and discharge planning
Number of subjects: 919
Study 16344017 — intervention group
Group type: COMPARATOR
Intervention: Control (no standardized rehabilitation and discharge planning)
Number of subjects: 919
Study 12051400 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX treated RA patients
Number of subjects: 119
Study 12051400 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 119
Study 12051400 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX treated RA patients with folic acid supplementation
Number of subjects: 119
Study 10658409 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 gauge open-end pencil point spinal needle
Number of subjects: 24
Study 10658409 — intervention group
Group type: COMPARATOR
Intervention: 25 gauge Quincke needle
Number of subjects: 24
Study 10658409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 8654899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ineraid cochlear implant users
Number of subjects: 41
Study 8654899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus cochlear implant users
Number of subjects: 41
Study 2162274 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal
Number of subjects: 0
Study 2162274 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium protein meal
Number of subjects: 0
Study 2162274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein meal
Number of subjects: 0
Study 2162274 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate control meal
Number of subjects: 0
Study 387001 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LRH, 500 micrograms, intramuscularly injected)
Number of subjects: 6
Study 387001 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study 29991338 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-gender IPCM with physical violence
Number of subjects: 738
Study 29991338 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-gender IPCM without physical violence
Number of subjects: 738
Study 29991338 — intervention group
Group type: EXPERIMENTAL
Intervention: Different-gender IPCM with physical violence
Number of subjects: 738
Study 29991338 — intervention group
Group type: EXPERIMENTAL
Intervention: Different-gender IPCM without physical violence
Number of subjects: 738
Study 30986809 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors (palbociclib or ribociclib) in combination with cetuximab
Number of subjects: 0
Study 30986809 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of palbociclib/cetuximab
Number of subjects: 0
Study 30986809 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors
Number of subjects: 0
Study 30986809 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies (CDK4/6 inhibitors with other agents)
Number of subjects: 0
Study 25265991 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing via telephone calls (average duration 9.5 minutes, conducted fortnightly)
Number of subjects: 26
Study 25265991 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with interpreter services
Number of subjects: 26
Study 23792937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1000 IU/day
Number of subjects: 95
Study 23792937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 1000 IU/day
Number of subjects: 95
Study 23792937 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol and Ergocalciferol (both treatments)
Number of subjects: 95
Study 21035237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg submucosally
Number of subjects: 30
Study 21035237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg intramuscularly
Number of subjects: 30
Study 21035237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid)
Number of subjects: 30
Study 20112595 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CM)
Number of subjects: 18
Study 20112595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17556681 — intervention group
Group type: EXPERIMENTAL
Intervention: RF+FV group (reduced fat intake and increased intake of water-rich foods)
Number of subjects: 97
Study 17556681 — intervention group
Group type: COMPARATOR
Intervention: RF group (reduced fat intake)
Number of subjects: 97
Study 15135483 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT 10 microg
Number of subjects: 52
Study 15135483 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT 100 microg
Number of subjects: 52
Study 15135483 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT 250 microg
Number of subjects: 52
Study 15135483 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT 250 microg (stage IV)
Number of subjects: 52
Study 15135483 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT
Number of subjects: 52
Study 15135483 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT antibodies
Number of subjects: 52
Study 11466984 — intervention group
Group type: EXPERIMENTAL
Intervention: Presumed non-effective reflexological treatment (Group A)
Number of subjects: 63
Study 11466984 — intervention group
Group type: EXPERIMENTAL
Intervention: Presumed effective reflexological treatment (Group B)
Number of subjects: 63
Study 11466984 — intervention group
Group type: COMPARATOR
Intervention: No treatment - only observation (Group C)
Number of subjects: 63
Study 9728931 — intervention group
Group type: EXPERIMENTAL
Intervention: LPONL(G)
Number of subjects: 0
Study 9728931 — intervention group
Group type: EXPERIMENTAL
Intervention: LPONL(A)
Number of subjects: 0
Study 7991126 — intervention group
Group type: EXPERIMENTAL
Intervention: MN BR test with electrical stimulation of the mental nerve
Number of subjects: 28
Study 2600755 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-rotary toothbrush
Number of subjects: 24
Study 2600755 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 24
Study 4448876 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling treatment
Number of subjects: 15
Study 4448876 — intervention group
Group type: COMPARATOR
Intervention: Viewing the operatory and professional staff
Number of subjects: 15
Study 30199900 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-viewing endoscopy
Number of subjects: 62
Study 30199900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopy
Number of subjects: 62
Study 30199900 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 62
Study 28371897 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted screening for at-risk alcohol use
Number of subjects: 3562
Study 28371897 — intervention group
Group type: COMPARATOR
Intervention: Universal screening for at-risk alcohol use
Number of subjects: 3562
Study 25887238 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational program for nursing home care staff on assessment and treatment of fecal incontinence
Number of subjects: 240
Study 25887238 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 240
Study 23190342 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (20 U per cycle, up to eight treatment cycles, treatment interval at least 85 days)
Number of subjects: 796
Study 22191131 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum Assisted Closure (VAC) therapy
Number of subjects: 67
Study 22191131 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 67
Study 19656069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ) 15 mg/kg in a single intake twice during pregnancy
Number of subjects: 1601
Study 19656069 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) 1500 mg sulfadoxine and 75 mg pyrimethamine in a single intake twice during pregnancy
Number of subjects: 1601
Study 19656069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 1601
Study 19656069 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 1601
Study 17985403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg
Number of subjects: 278
Study 17985403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg
Number of subjects: 278
Study 17985403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg
Number of subjects: 278
Study 17985403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 12920042 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) infusion
Number of subjects: 10
Study 12920042 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline infusion (placebo)
Number of subjects: 10
Study 10839552 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (dosage and duration not specified)
Number of subjects: 0
Study 10839552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs, alpha-blocking agents, anticholinergic agents or other therapies
Number of subjects: 0
Study 9099447 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-area method (5h AUC)
Number of subjects: 0
Study 9099447 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetrical confidence intervals
Number of subjects: 0
Study 9099447 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point short-term AUC
Number of subjects: 0
Study 8404314 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem SR
Number of subjects: 168
Study 8404314 — intervention group
Group type: COMPARATOR
Intervention: diltiazem HCL
Number of subjects: 168
Study 3533264 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 150 mg daily
Number of subjects: 41
Study 3533264 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa 750 mg daily
Number of subjects: 41
Study 28580810 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Empowerment Solutions (YES) program
Number of subjects: 367
Study 27013473 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 63
Study 27013473 — intervention group
Group type: COMPARATOR
Intervention: Sham electro-acupuncture (SEA)
Number of subjects: 63
Study 25038985 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency deep TMS treatment
Number of subjects: 115
Study 25038985 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency deep TMS treatment
Number of subjects: 115
Study 25038985 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 115
Study 22858177 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaprazan 200 mg once daily for 7 days
Number of subjects: 30
Study 22858177 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 50 mg TID for 7 days
Number of subjects: 30
Study 22858177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of revaprazan and itopride
Number of subjects: 30
Study 20133068 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (500 μg of sodium selenite during RT and 300 μg on non-RT days)
Number of subjects: 81
Study 20133068 — intervention group
Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 81
Study 20133068 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (SG)
Number of subjects: 81
Study 18603821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 17
Study 18603821 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 17
Study 15749950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental screening program (study group)
Number of subjects: 4500
Study 15749950 — intervention group
Group type: COMPARATOR
Intervention: No dental screening program (control group)
Number of subjects: 4500
Study 12623814 — intervention group
Group type: EXPERIMENTAL
Intervention: 130 degrees short arc length intrastromal corneal ring segments (ICRS) with thicknesses ranging from 0.25 to 0.50 mm by 0.05 mm increments
Number of subjects: 10
Study 10368794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DHEAS (50 mg/day)
Number of subjects: 22
Study 10368794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DHEAS (50 mg/day) + transdermal estradiol (50 micrograms/patch)
Number of subjects: 22
Study 10368794 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (50 micrograms/day)
Number of subjects: 22
Study 10368794 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 22
Study 10368794 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups treated with estradiol alone or plus DHEAS
Number of subjects: 22
Study 8904583 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 14
Study 8904583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1877335 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular hydrotherapy for 31/2 weeks
Number of subjects: 61
Study 1877335 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control) for 31/2 weeks
Number of subjects: 61
Study 7174915 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 8‐methoxypsoralen (8‐MOP) 0.1%
Number of subjects: 73
Study 7174915 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 8‐methoxypsoralen (8‐MOP) 0.5%
Number of subjects: 73
Study 7174915 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 8‐methoxypsoralen (8‐MOP) 1%
Number of subjects: 73
Study 7174915 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 8‐methoxypsoralen (8‐MOP)
Number of subjects: 73
Study 31102024 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 375
Study 31102024 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 plus pertuzumab
Number of subjects: 375
Study 29604316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.425% phytate/F toothpaste
Number of subjects: 0
Study 29604316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.85% phytate/F toothpaste
Number of subjects: 0
Study 29604316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.85% phytate/Zn/F toothpaste
Number of subjects: 0
Study 29604316 — intervention group
Group type: EXPERIMENTAL
Intervention: F-only toothpaste (1150 ppm NaF)
Number of subjects: 0
Study 29604316 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn/F toothpaste (0.3% ZnCl2)
Number of subjects: 0